B
15.75
-0.27 (-1.69%)
| 前收盘价格 | 16.02 |
| 收盘价格 | 15.45 |
| 成交量 | 1,860,641 |
| 平均成交量 (3个月) | 1,783,577 |
| 市值 | 1,608,279,808 |
| 股市价格/股市净资产 (P/B) | 5.69 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2025 - 20 Aug 2025 |
| 稀释每股收益 (EPS TTM) | -9.25 |
| 总债务/股东权益 (D/E MRQ) | 13.68% |
| 流动比率 (MRQ) | 2.33 |
| 营业现金流 (OCF TTM) | -644.94 M |
| 杠杆自由现金流 (LFCF TTM) | -394.10 M |
| 资产报酬率 (ROA TTM) | -129.99% |
| 股东权益报酬率 (ROE TTM) | -316.82% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Biohaven Ltd. | 看跌 | 看跌 |
AIStockmoo 评分
1.8
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.75 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 11.96% |
| 机构持股比例 | 90.76% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Suvretta Capital Management, Llc | 31 Dec 2024 | 5,620,271 |
| Bellevue Group Ag | 31 Dec 2024 | 2,040,853 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 57.00 (Baird, 261.91%) | 购买 |
| 中 | 55.00 (249.21%) | |
| 低 | 21.00 (RBC Capital, 33.33%) | 保留 |
| 平均值 | 44.33 (181.46%) | |
| 总计 | 2 购买, 1 保留 | |
| 平均价格@调整类型 | 17.29 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JP Morgan | 18 Jun 2025 | 55.00 (249.21%) | 购买 | 14.39 |
| RBC Capital | 19 May 2025 | 21.00 (33.33%) | 保留 | 15.75 |
| 13 May 2025 | 54.00 (242.86%) | 购买 | 19.51 | |
| Baird | 28 Apr 2025 | 57.00 (261.90%) | 购买 | 21.74 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合